Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRA023 Safety and PK in Healthy Caucasian and Japanese Volunteers
NCT05354349Phase 1Completed
- Sponsor
- Prometheus Biosciences
- Start
- Apr 2022
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tulisokibart in ulcerative colitis (UC) and Crohn's disease (4 arms), sponsored by Prometheus Biosciences. Primary endpoints: Treatment Emergent Adverse Events up to 14 Weeks, F% in Caucasian subjects up to 10 Weeks and 2 more. Started Apr 2022; status: completed.
02
Drugs
tulisokibart
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT05354349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05354349.